Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Autologous genetically modified gamma-delta T cells
INB-400 · 1 trial · 1 indication
Date of first dose to date of death by any cause
\<30% dose limiting toxicity (DLT) observed with dose
Date of first dose to date of death by any cause
Date of first dose to date of death by any cause
| Arm | Type | Description |
|---|---|---|
| 1) Autologous Newly Diagnosed Disease: Phase 2 Arm A | EXPERIMENTAL | Arm A subjects with newly diagnosed disease will receive autologously derived, genetically modified gamma-delta T cells administered with maintenance temozolomide. |
| 2) Allogeneic Relapsed Disease: Phase 1b and Phase 2 | EXPERIMENTAL | Phase 1b subjects with relapsed disease will have allogeneic derived, genetically modified gamma-delta T cells administered with temozolomide |
| 3) Allogeneic Newly Diagnosed Disease: Phase 2 Arm C | EXPERIMENTAL | Arm C subjects with newly diagnosed disease will receive allogeneic derived, genetically modified gamma-delta T cells administered with maintenance temozolomide. |
| Name | Type | Description |
|---|---|---|
| Autologous genetically modified gamma-delta T cells | BIOLOGICAL | Arm A: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance |
| Allogeneic genetically modified gamma-delta T cells | BIOLOGICAL | Phase 1b and Arm B: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with D1 of TMZ 150mg/m2 Arms C: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance |
Inclusion Criteria: * Subjects with histologically or cytologically confirmed history of IDH-wild type glioblastoma * Phase 1b and Arm B of Phase 2: Subjects must have completed no more than one standard therapy for glioblastoma, have received no prior Avastin® therapy (unless solely used for ed...
INB-400 is an investigational cell therapy being developed by IN8bio, Inc. for glioblastoma, a type of brain cancer. It consists of autologous genetically modified gamma-delta T cells, meaning the cells are derived from the patient and engineered before being returned to the patient. It is in Phase 1 clinical development.
INB-400 is being studied for use in patients with recurrent or newly diagnosed glioblastoma. It is given in combination with maintenance temozolomide, a standard chemotherapy, as part of a Phase 1b/2 clinical trial. The trial is currently active but not recruiting.
INB-400 is developed by IN8bio, Inc., a biotechnology company. IN8bio trades on the Nasdaq under the ticker symbol INAB. The company is focused on developing gamma-delta T cell therapies for cancer.
INB-400 is in Phase 1 clinical development. It is being evaluated in a Phase 1b/2 trial for glioblastoma. The trial is active but not recruiting, and no completed trials have been reported. INB-400 has received orphan drug designation from the FDA.
INB-400 is being studied in one clinical trial, NCT05664243, titled "A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma." The trial is active but not recruiting and has enrolled 4 participants in the United States.
Yes, INB-400 is also known as autologous genetically modified gamma-delta T cells. This alternative name describes the composition of the therapy: it uses the patient's own gamma-delta T cells that have been genetically modified. The trial also includes an allogeneic arm, but INB-400 specifically refers to the autologous version.